How to treat BRAF mutant metastatic melanoma?
Melanoma is a malignant tumour arising from melanocytes and is the most aggressive type of skin cancer. In advanced disease standard treatments are largely ineffective. About 40% of cutaneous melanomas carry BRAF mutations-more common in younger patients-and these are linked to more aggressive behaviour and a higher risk of brain metastasis. Over the past decade, targeted therapies (TT) using BRAF and MEK inhibitors (BRAFi, MEKi), along with immune checkpoint inhibitors (ICI), have significantly improved response rates and survival in metastatic melanoma.
Authors
- Milena Casula (ORCID: https://orcid.org/0000-0002-5079-9864)
- Giuseppe Palmieri (ORCID: https://orcid.org/0000-0002-4350-2276)
- Maria Cristina Sini (ORCID: https://orcid.org/0000-0003-2796-6166)
- Antonella Manca (ORCID: https://orcid.org/0000-0003-2497-1541)
- Marina Pisano (ORCID: https://orcid.org/0000-0002-0649-1010)
Institutions
- University of Sassari (IT)
- National Academies of Sciences, Engineering, and Medicine (US)
- Institute of Genetic and Biomedical Research (IT)
- National Research Council (IT)
Publication Details
- Journal
- Personalized Medicine
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/17410541.2025.2595903
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00